Peptide purity: what a COA can and cannot confirm
A useful document — but not a substitute for sterile compounding and clinical oversight.
TL;DR
- A certificate of analysis confirms identity and purity of the peptide molecule — usually with HPLC and mass spectrometry.
- It does not confirm sterility, the manufacturing environment, or whether the product is safe to inject.
- Patients should rely on the quality system around the COA — 503A licensing, USP 797 sterility, PCAB accreditation — not the COA alone.
What it is
A certificate of analysis (COA) is the paper trail that comes with a peptide vial or active pharmaceutical ingredient (in plain English: a document listing what tests the supplier ran and what the results were). Standard panels include identity by mass spectrometry, purity by HPLC (high-performance liquid chromatography — a separation technique that measures how much of each component is in the sample), water content, and residual solvent levels. Better suppliers also report endotoxin and microbial limits.
How it works
Think of a COA as the label on a bottle of olive oil. It tells you what is in the bottle — extra virgin, single origin, acidity level — but not whether the kitchen that bottled it was clean. HPLC and mass spectrometry confirm the molecule. Endotoxin and microbial testing confirm what is not supposed to be in the vial. Sterility testing confirms how the product was handled. Each test answers a different question, and all of them together start to approach “safe to inject.”
Who asks about it
Patients and clinicians come to this topic when comparing 503A pharmacies, vetting research-use-only sources online, or evaluating which compounding pharmacy a clinic uses. Many have seen a printed COA and assumed it meant the product was equivalent to an FDA-approved drug.
What the research says
The U.S. compounding framework distinguishes two pharmacy types. 503A pharmacies do patient-specific compounding under state license. 503B outsourcing facilities are FDA-registered and compound at the batch level (FDA, Compounding Quality Act). USP General Chapter 797 sets sterile compounding standards for both (USP 797). A compounded product from a high-purity active pharmaceutical ingredient at a 797-compliant 503A pharmacy is materially different from a gray-market vial of unknown origin. The COA is a necessary input, not a sufficient one.
What to know before considering it
A COA from a high-quality API supplier covers the molecule. A COA from a 503A pharmacy after compounding covers the finished product, often including sterility and endotoxin. Patients should ask their clinic which pharmacy they use, whether it is PCAB-accredited, and whether the pharmacy provides batch-level COAs. Compounded peptides are not FDA-approved drugs even when the COA is excellent.
The Halftime POV
The right question is not “do you have a COA.” Every supplier has a COA. The right questions are: who tested it, against what standard, at which step, and is the whole quality system around the COA strong enough to trust the result. We work only with state-licensed 503A pharmacies that meet USP 797, hold PCAB accreditation where possible, and trace ingredients to FDA-approved APIs.
Related reading:
- The certificate of analysis: how to read a pharmacy’s quality paperwork
- Sterility testing in compounded peptides: what the standards require
- 503A pharmacy quality standards: what to look for
- Gray-market research-use-only peptides: the real risk profile
FAQ
Q: What does a peptide certificate of analysis (COA) actually test? A: A typical COA reports identity (mass spectrometry), purity (HPLC), water content, residual solvents, acetate content, and sometimes endotoxin and microbial limits. The exact panel varies by source and standard followed.
Q: Does HPLC purity mean the peptide is safe? A: No. HPLC measures how much of the target peptide is present compared with related impurities. It does not confirm sterility, endotoxin content, or whether the product was made under aseptic conditions appropriate for injection.
Q: How do I verify peptide quality as a patient? A: Patients should request that their clinician work only with a state-licensed 503A pharmacy that meets USP 797 sterile compounding standards, holds PCAB accreditation when possible, and provides COAs traceable to FDA-approved active pharmaceutical ingredients.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
